Study finds MPS2 scores are highly reproducible across DRE and non-DRE urine samples alike. “This study reinforces the value of MPS2 as a non-invasive diagnostic tool that delivers consistent and ...

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio It is well established that ...

The MarketWatch News Department was not involved in the creation of this content. Validation Results Pave the Way for Clinical Studies Focused on Transforming Patient Outcomes inInflammatory ...

Early Completion of Model-Assisted Designs for Dose-Finding Trials Accurate assessment of a molecular classifier that guides patient care is of paramount importance in precision oncology. Recent years ...

PHOENIX, AZ, UNITED STATES, June 2, 2025 /EINPresswire.com/ -- Precision Epigenomics, a biotechnology company advancing epigenetic-based diagnostics, today announced ...